Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 518454, 15 pages
http://dx.doi.org/10.1155/2015/518454
Research Article

The Effect of Tou Nong San on Transplanted Tumor Growth in Nude Mice

1Oncologic Department, Jiangsu Province Hospital of TCM, Nanjing 210029, Jiangsu, China
2Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, China

Received 12 December 2014; Revised 23 January 2015; Accepted 24 January 2015

Academic Editor: Pradeep Visen

Copyright © 2015 Liang-Hua Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, C. Desantis, and A. Jemal, “Colorectal cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 2, pp. 104–117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Akagi, Y. Adachi, T. Kinugasa, Y. Oka, T. Mizobe, and K. Shirouzu, “Lymph node evaluation and survival in colorectal cancer: review of population-based, prospective studies,” Anticancer Research, vol. 33, no. 7, pp. 2839–2848, 2013. View at Google Scholar · View at Scopus
  3. L.-H. Fang, R.-P. Wang, S.-Y. Hu, L. Zhang, and S.-L. Liu, “Tounongsan extract induces apoptosis in cultured Raji cells,” Chinese Journal of Integrative Medicine, vol. 18, no. 7, pp. 522–528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. W. L. T. Kan, C. H. Cho, J. A. Rudd, and G. Lin, “Study of the anti-proliferative effects and synergy of phthalides from Angelica sinensis on colon cancer cells,” Journal of Ethnopharmacology, vol. 120, no. 1, pp. 36–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Yin, C. Wang, A. Mody et al., “The effect of z-ligustilide on the mobility of human glioblastoma T98G cells,” PLoS ONE, vol. 8, no. 6, Article ID e66598, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. K. K.-W. Auyeung, P.-C. Law, and J. K.-S. Ko, “Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft,” Oncology Reports, vol. 28, no. 6, pp. 2188–2194, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. Q. C. Chen, J. P. Lee, W. Y. Jin et al., “Cytotoxic constituents from Angelicae Sinensis radix,” Archives of Pharmacal Research, vol. 30, no. 5, pp. 565–569, 2007. View at Publisher · View at Google Scholar
  8. H. Qi, L. Wei, Y. Han, Q. Zhang, A. S.-Y. Lau, and J. Rong, “Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2,” International Journal of Oncology, vol. 36, no. 3, pp. 725–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. Johnson, P. Gulhati, B. A. Rampy et al., “Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer,” Journal of the American College of Surgeons, vol. 210, no. 5, pp. 767–776, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Awasthi, P. L. Yen, M. A. Schwarz, and R. E. Schwarz, “The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer,” Journal of Cellular Biochemistry, vol. 113, no. 3, pp. 784–791, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Glienke, L. Maute, J. Wicht, and L. Bergmann, “The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines,” Tumor Biology, vol. 33, no. 3, pp. 757–765, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Samuels, Z. Wang, A. Bardelli et al., “High frequency of mutations of the PIK3CA gene in human cancers,” Science, vol. 304, no. 5670, p. 554, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. H. Cardone, N. Roy, H. R. Stennicke et al., “Regulation of cell death protease caspase-9 by phosphorylation,” Science, vol. 282, no. 5392, pp. 1318–1321, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. J. C. Martinou and D. R. Green, “Breaking the mitochondrial barrier,” Nature Reviews Molecular Cell Biology, vol. 2, no. 1, pp. 63–67, 2001. View at Google Scholar
  15. Y. A. Lazebnik, S. H. Kaufmann, S. Desnoyers, G. G. Poirier, and W. C. Earnshaw, “Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE,” Nature, vol. 371, no. 6495, pp. 346–347, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. I. M. Ghobrial, T. E. Witzig, and A. A. Adjei, “Targeting apoptosis pathways in cancer therapy,” CA Cancer Journal for Clinicians, vol. 55, no. 3, pp. 178–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Mohamad, A. Gutiérrez, M. Núñez et al., “Mitochondrial apoptotic pathways,” Biocell, vol. 29, no. 2, pp. 149–161, 2005. View at Google Scholar · View at Scopus
  18. B. M. Mow, A. L. Blajeski, J. Chandra, and S. H. Kaufmann, “Apoptosis and the response to anticancer therapy,” Current Opinion in Oncology, vol. 13, no. 6, pp. 453–462, 2001. View at Google Scholar
  19. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, “Vascular endothelial growth factor (VEGF) and its receptors,” The FASEB Journal, vol. 13, no. 1, pp. 9–22, 1999. View at Google Scholar · View at Scopus
  20. D. Hanahan and J. Folkman, “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis,” Cell, vol. 86, no. 3, pp. 353–364, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Cassano, C. Bagalá, C. Battelli et al., “Expression of vascular endothelial growth factor, mitogen-activated Protein kinase and p53 in human colorectal cancer,” Anticancer Research, vol. 22, no. 4, pp. 2179–2184, 2002. View at Google Scholar · View at Scopus
  22. T. Yamaguchi, H. Bando, T. Mori et al., “Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis,” Cancer Science, vol. 98, no. 3, pp. 405–410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Charpin, B. Devictor, D. Bergeret et al., “CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors,” The American Journal of Clinical Pathology, vol. 103, no. 4, pp. 443–448, 1995. View at Google Scholar · View at Scopus
  24. H. M. DeLisser, P. J. Newman, and S. M. Albelda, “Molecular and functional aspects of PECAM-1/CD31,” Immunology Today, vol. 15, no. 10, pp. 490–495, 1994. View at Publisher · View at Google Scholar · View at Scopus